In patients with AMI who have received long-term treatment with SGLT2 inhibitors, a notable reduction in inflammatory responses, infarct sizes, and instances of stress-induced hyperglycemia has been observed (42). The gene discussed is SLC5A2; the disease is Hyperglycemia.